David S. Hong MD
Associate Vice President of Clinical Research M.D. Anderson Cancer CenterDr. David S. Hong is a Professor, Deputy Chairman in the Department of Investigational Cancer Therapeutics (Phase I Program), and Associate Vice President of Clinical Research at The University of Texas MD Anderson Cancer Center.
Dr. Hong was instrumental in forming one of the largest and most innovative Phase 1 clinical trial units in the world, with over 1200 patients enrolled in clinical trials in FY2018 and over 228 active ongoing clinical trials.
Dr. Hong has been the Principal Investigator of over 100 research protocols that involve a wide range of sponsors, including the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute.
He has been involved in the early development of cabozantinib, siltuximab, dabrafenib, trametinib, regorafenib, lenvatinib,and larotrectinib that have led to FDA approval.
He is an expert on c-Met ,NTRK, and KRAS and has led several national trials such as the c-Met amplified, c-Met exon 14 deleted, and NTRK arms of the NCI-MATCH trial. He been awarded the ASCO Young Investigator Award, the Jesse Jones award, Best Boss award at MD Anderson, Irwin Krakoff Award for Clinical Research and the Gerald P. Bodey award for education and Mentor of the year award in the Division of Cancer Medicine, MD Anderson.
WEDNESDAY, OCTOBER 28
1:15 PM Designing Trials in the Age of Rapidly Developing Innovation
We have adaptive design, but what else can be considered in diverse approaches to treat cancer? What have we learned about what else might be considered to augment with real world evidence and other data sets that could be valuable to understand the safety and effectiveness of a new molecule? How can industry be “better” at designing trials to utilize resources in the best way possible?
In Partnership With :
QUESTIONS?
Contact us: 1-800-882-8684
Email: enquiry@iqpc.com
©2024 IQPC. All rights reserved.
